Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
ProMIS Neurosciences Inc. (Nasdaq: PMN) is a clinical-stage biotechnology company developing therapeutic antibodies and vaccines that selectively target toxic misfolded protein oligomers in neurodegenerative and other misfolded protein diseases. News about ProMIS frequently centers on its lead Alzheimer’s disease program, PMN310, and the company’s biomarker-driven clinical strategy.
Investors following PMN can expect regular updates on the PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer’s disease. Company releases describe PRECISE-AD as a randomized, double-blind, placebo-controlled, multiple ascending dose study evaluating safety, tolerability, pharmacokinetics and biomarker effects of PMN310 in patients with mild cognitive impairment due to AD and mild AD. News items have highlighted enrollment milestones, DSMB recommendations to proceed to higher dose cohorts, and reports that no amyloid-related imaging abnormalities (ARIA) or treatment-related serious adverse events were observed in the cohorts discussed.
ProMIS also issues news on peer-reviewed publications and scientific analyses related to its approach. Recent communications describe publications on the relationship between antibody selectivity for soluble amyloid-beta oligomers and clinical efficacy, as well as analyses supporting plasma phosphorylated tau (pTau) as a potential early predictor of clinical benefit. These publications are referenced by the company as supporting its focus on oligomer-only targeting and its use of plasma pTau as a central endpoint in PRECISE-AD.
Additional PMN news covers corporate and regulatory developments, including the granting of FDA Fast Track designation for PMN310, participation in healthcare investment conferences, board appointments, and capital markets actions such as a one-for-twenty-five reverse stock split and at-the-market offering arrangements. Together, these updates provide context on ProMIS Neurosciences’ clinical progress, scientific rationale and financing activities for those tracking PMN stock and its Alzheimer’s and broader neurodegeneration pipeline.
ProMIS Neurosciences Inc. (TSX: PMN, Nasdaq: PMN), a biotechnology firm focused on antibody therapeutics for neurodegenerative diseases, has announced that CEO Gail Farfel, Ph.D., will present at the Oppenheimer 33rd Annual Conference on March 13, 2023, at 12:30 p.m. ET. The presentation will be webcasted and available on ProMIS’ website for 30 days following the event.
The company specializes in targeting toxic misfolded proteins linked to conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple system atrophy. ProMIS employs proprietary platforms to discover novel antibody therapeutics.
ProMIS Neurosciences (TSX: PMN) announced a $7.4 million private placement and appointed Gail Farfel, Ph.D. as its CEO as of September 19, 2022. The company is progressing toward an investigational new drug (IND) submission for PMN310, targeting Alzheimer’s disease, with plans to enroll the first subject in a Phase 1a trial in the first half of 2023. Financial highlights for Q3 2022 include a net loss of $6.0 million and research expenses of $4.6 million, up from $0.8 million year-over-year. Cash reserves decreased to $4.0 million.
ProMIS Neurosciences Inc. (Nasdaq: PMN) has closed a fully subscribed private placement of 1,383,755 Units at US$5.40 each, raising gross proceeds of US$7,472,277. Each Unit consists of a Common Share and a quarter Warrant, with each full Warrant exercisable at US$7.50 for five years. Proceeds will fund the first-in-human study of lead candidate PMN310 in 2023, pending FDA approval, while also supporting IP expansion and working capital. ProMIS focuses on developing antibody therapeutics for neurodegenerative diseases like Alzheimer’s, ALS, and MSA.
ProMIS Neurosciences (Nasdaq: PMN) has appointed Gail M. Farfel, Ph.D., as its new Chief Executive Officer, effective September 19, 2022. With over 25 years of experience in neurology drug development, Dr. Farfel aims to lead ProMIS towards becoming a clinical-stage biotechnology company with multiple product opportunities. The company achieved significant milestones in the past 18 months, including a successful Nasdaq listing and the IND submission for their lead Alzheimer’s drug, PMN310, expected by year-end.